Template:Congestive heart failure: Difference between revisions

	Congestive Heart Failure Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology Systolic Dysfunction Diastolic Dysfunction HFpEF HFrEF
Causes
Differentiating Congestive heart failure from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Clinical Assessment
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Cardiac MRI
Echocardiography
Exercise Stress Test
Myocardial Viability Studies
Cardiac Catheterization
Other Imaging Studies
Other Diagnostic Studies
Treatment
Invasive Hemodynamic Monitoring
Medical Therapy:
Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF Diuretics ACE Inhibitors Angiotensin receptor blockers Aldosterone Antagonists Beta Blockers Ca Channel Blockers Nitrates Hydralazine Positive Inotropics Anticoagulants Angiotensin Receptor-Neprilysin Inhibitor Antiarrhythmic Drugs Nutritional Supplements Hormonal Therapies Drugs to Avoid Drug Interactions Treatment of underlying causes Associated conditions
Exercise Training
Surgical Therapy: Biventricular Pacing or Cardiac Resynchronization Therapy (CRT) Implantation of Intracardiac Defibrillator Ultrafiltration Cardiac Surgery Left Ventricular Assist Devices (LVADs) Cardiac Transplantation
ACC/AHA Guideline Recommendations Initial and Serial Evaluation of the HF Patient Hospitalized Patient Patients With a Prior MI Sudden Cardiac Death Prevention Surgical/Percutaneous/Transcather Interventional Treatments of HF Patients at high risk for developing heart failure (Stage A) Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B) Patients with current or prior symptoms of heart failure (Stage C) Patients with refractory end-stage heart failure (Stage D) Coordinating Care for Patients With Chronic HF Quality Metrics/Performance Measures
Implementation of Practice Guidelines
Congestive heart failure end-of-life considerations
Specific Groups: Special Populations Patients who have concomitant disorders Obstructive Sleep Apnea in the Patient with CHF NSTEMI with Heart Failure and Cardiogenic Shock
Congestive heart failure On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Congestive heart failure
CDC on Congestive heart failure
Congestive heart failure in the news
Blogs on Congestive heart failure
Directions to Hospitals Treating Congestive heart failure
Risk calculators and risk factors for Congestive heart failure

VisualWikitext

@@ Line 1: / Line 1: @@
-{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
+{| class="infobox bordered" style="width:15%; text-align:left; font-size:90%; background:AliceBlue"
 |-
-| colspan="1" style="text-align:center; background:DarkGray" |
+| colspan="1" style="text-align:center; background:DarkGray" |'''Congestive Heart Failure Microchapters'''
-'''Congestive heart failure Microchapters
-'''
 |- bgcolor="LightGrey"
 !
@@ Line 23: / Line 22: @@
 !
 [[Congestive heart failure overview|Overview]]
+|-
+!
+|- bgcolor="Pink"
+!
+[[Congestive heart failure historical perspective|Historical Perspective]]
 |-
 !
@@ Line 34: / Line 39: @@
 |- bgcolor="Pink"
 !
-[[Congestive heart failure pathophysiology|Pathophysiology]]
+Pathophysiology
+:[[Congestive heart failure pathophysiology#Systolic dysfunction|Systolic Dysfunction]]
+:[[Diastolic dysfunction pathophysiology|Diastolic Dysfunction]]
+:[[Congestive heart failure with preserved EF|HFpEF]]
+:[[Congestive heart failure with reduced EF|HFrEF]]
 |-
 !
@@ Line 43: / Line 52: @@
 |-
 !
 |- bgcolor="Pink"
 !
@@ Line 48: / Line 58: @@
 |-
 !
 |- bgcolor="Pink"
 !
@@ Line 57: / Line 68: @@
 !
 [[Congestive heart failure risk factors|Risk Factors]]
+|-
+!
+|- bgcolor="Pink"
+!
+[[Congestive heart failure Screening|Screening]]
 |-
 !
@@ Line 107: / Line 124: @@
 |-
 !
 |- bgcolor="LightSkyBlue"
 !
@@ Line 112: / Line 130: @@
 |-
 !
 |- bgcolor="LightSkyBlue"
 !
@@ Line 138: / Line 157: @@
 |- bgcolor="LightSkyBlue"
 !
-[[Congestive heart failure endomyocardial biopsy|Endomyocardial biopsy]]
+[[Congestive heart failure Other Imaging Studies|Other Imaging Studies]]
+|-
+!
+|- bgcolor="LightSkyBlue"
+!
+[[Congestive heart failure other diagnostic studies|Other Diagnostic Studies]]
 |-
 !
@@ Line 157: / Line 182: @@
 !
 Medical Therapy:
+|- bgcolor="PaleTurquoise"
+!
+: [[Congestive heart failure pharmacotherapy|Summary]]
+|- bgcolor="PaleTurquoise"
+!
 : [[Congestive heart failure acute pharmacotherapy|Acute Pharmacotherapy]]
-: [[Chronic Pharmacotherapy]]:
+|- bgcolor="PaleTurquoise"
+!
+: [[Congestive heart failure with preserved EF pharmacotherapy|Chronic Pharmacotherapy in HFpEF]]
+|- bgcolor="PaleTurquoise"
+!
+: [[Congestive heart failure chronic pharmacotherapy|Chronic Pharmacotherapy in HFrEF]]
 :: [[Congestive heart failure diuretics|Diuretics]]
 :: [[Congestive heart failure ACE inhibitors|ACE Inhibitors]]
@@ Line 169: / Line 204: @@
 :: [[Congestive heart failure positive inotropics|Positive Inotropics]]
 :: [[Congestive heart failure anticoagulants|Anticoagulants]]
+:: [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|Angiotensin Receptor-Neprilysin Inhibitor]]
 :: [[Congestive heart failure antiarrhythmic Drugs|Antiarrhythmic Drugs]]
 :: [[Congestive heart failure other pharmacotherapies#Nutritional Supplements|Nutritional Supplements]]
-::[[Congestive heart failure omega-3-fatty acid|Omega-3-Fatty Acid]]
 :: [[Congestive heart failure other pharmacotherapies#Hormonal Therapies|Hormonal Therapies]]
 :[[Congestive heart failure drugs to avoid|Drugs to Avoid]]
@@ Line 200: / Line 235: @@
 |- bgcolor="PaleTurquoise"
 !
-ACCF/AHA Guideline for the Management of Heart Failure
+ACC/AHA Guideline Recommendations
-: [[2013 ACCF/AHA Guideline Definition of HF|Definitions of HFrEF and HFpEF]]
+: [[Congestive heart failure AHA recommendations|Initial and Serial Evaluation of the HF Patient]]
-: [[2013 ACCF/AHA Guideline Initial and Serial Evaluation of the HF Patient|Evaluation of the HF]]
+: [[Congestive heart failure AHA recommendations for hospitalized patient|Hospitalized Patient]]
-: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|At high risk for HF but without structural heart disease or symptoms of HF (Stage A)]]
-: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Structural heart disease but without signs or symptoms of HF (Stage B)]]
-: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Structural heart disease with prior or current symptoms of HF (Stage C)]]
-: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Refractory HF requiring specialized interventions (Stage D)]]
-: [[2013 ACCF/AHA Guideline The Hospitalized Patient|Hospitalized Patient]]
-: [[2013 ACCF/AHA Guideline Surgical/Percutaneous/Transcather Interventional Treatments of HF|Surgical/Percutaneous/Transcather Interventional Treatments]]
-: [[2013 ACCF/AHA Guideline Coordinating Care for Patients With Chronic HF|Coordinating Care]]
-: [[2013 ACCF/AHA Guideline Quality Metrics/Performance Measures|Quality Metrics/Performance Measures]]
-|- bgcolor="PaleTurquoise"
-!
-ACC/AHA Guideline Recommendations
-: [[Congestive heart failure AHA recommendations for hospitalized patient|Hospitalized Patients]]
 : [[Congestive heart failure AHA recommendations for patients with a prior MI|Patients With a Prior MI]]
 : [[Congestive heart failure sudden cardiac death prevention|Sudden Cardiac Death Prevention]]
+: [[Congestive heart failure AHA recommendations Surgical/Percutaneous/Transcather Interventional Treatments of HF|Surgical/Percutaneous/Transcather Interventional Treatments of HF]]
 : [[Congestive heart failure treatment of patients at high risk for developing heart failure (Stage A)|Patients at high risk for developing heart failure (Stage A)]]
 : [[Congestive heart failure treatment of patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)|Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)]]
 : [[Congestive heart failure treatment of patients with current or prior symptoms of heart failure (Stage C)|Patients with current or prior symptoms of heart failure (Stage C)]]
 : [[Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D)|Patients with refractory end-stage heart failure (Stage D)]]
+: [[Congestive heart failure AHA recommendations Coordinating Care for Patients With Chronic HF|Coordinating Care for Patients With Chronic HF]]
+: [[Congestive heart failure AHA recommendations Quality Metrics/Performance Measures|Quality Metrics/Performance Measures]]
 |-
 !
@@ Line 243: / Line 268: @@
 : [[Congestive heart failure treatment of patients who have concomitant disorders|Patients who have concomitant disorders]]
 : [[Congestive heart failure and obstructive sleep apnea|Obstructive Sleep Apnea in the Patient with CHF]]
+: [[Unstable angina / non ST elevation myocardial infarction Heart Failure and Cardiogenic Shock|NSTEMI with Heart Failure and Cardiogenic Shock]]
 |-
 !
@@ Line 326: / Line 352: @@
 |- bgcolor="LightYellow"
 !
-[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]</small>
+[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]
 |-
 !
@@ Line 342: / Line 368: @@
 !
+|-
 |}

Template:Congestive heart failure: Difference between revisions

Latest revision as of 17:06, 23 December 2019

Navigation menu